Table 3.
Meta-analysis results
| Outcome | n studies | Number of patients | Statistical method | Effect estimate, mean (95% CI) | Statistical heterogeneity, I2 and P-value |
|---|---|---|---|---|---|
| All-cause mortality | |||||
| <12-month follow-up | 13 | 962 | Relative risk (fixed effects) | 1.03 (0.70–1.53) | 0%, 0.95 |
| >12-month follow-up | 4 | 328 | Relative risk (fixed effects) | 0.91 (0.78–1.06) | 41%, 0.17 |
| All hospital admissions | |||||
| <12-month follow-up | 8 | 659 | Relative risk (fixed effects) | 0.79 (0.58–1.07) | 0%, 0.54 |
| >12-month follow-up | 4 | 2658 | Relative risk (fixed effects) | 0.96 (0.90–1.02) | 37%, 0.19 |
| Hospital admission due to heart failure | |||||
| <12-month follow-up | 7 | 569 | Relative risk (fixed effects) | 0.72 (0.52–0.99) | 16%, 0.31 |
| HRQoL | |||||
| MLWHF | 6 | 700 | Weighted mean difference (random effects) | −10.33 (−15.89 to −4.77) | 71%, 0.004 |
| All scales | 9 | 779 | Standardized mean difference (random effects) | −0.63 (−0.8 to −0.37) | 79%, <0.0001 |
MLWHF, Minnesota Living with Heart Failure questionnaire.